StemCells Inc (NASDAQ:STEM), in cooperation with the International Society for Stem Cell Research (ISSCR), has posted a video of the presentation made by the Company’s vice president of clinical research and chief medical officer Dr. Stephen Huhn, at the ISSCR 2015 Annual Meeting. Held last month in Stockholm, the meeting was attended by approximately 3,000 scientists, clinicians and biotechnology industry professionals from 55 countries, who gathered to share new data and discuss advances within the stem cell field that are currently being explored by peers as potential therapeutic treatments.

The video provides a comprehensive review of StemCells, Inc.’s platform technology, which is based on transplantation of the Company’s proprietary HuCNS-SC® cells (purified human neural stem cells), as well as the Company’s Phase I and Phase I/II clinical trials completed to-date and the Phase II proof-of-concept trials currently underway.

Regarding the Phase I/II trial in thoracic spinal cord injury (SCI) completed in April 2015, Dr. Huhn stated, “Our primary focus in this study was to evaluate safety and also to look for even small signs of an effect that went beyond the possibility of spontaneous recovery. The pattern of sensory gains observed are both durable and meaningful, and indicate that the transplantation has impacted the function of damaged neural pathways.” He further postulates, “The corollary of the sensory improvements we observed in our Phase I/II thoracic SCI trial could well be improved motor function in the upper extremities of patients with cervical spinal cord injuries participating in our Phase II trial.”

Dr. Huhn also presented the top-line outcomes, at ISSCR 2015, from the Company’s Phase I/II study in the advanced form of dry AMD, referred to as geographic atrophy (GA), which was completed in June 2015. Dr. Huhn discussed the methodology used to analyze the progression of geographic atrophy in this study, which involved the first neural stem cell transplants conducted in the eye for a retinal degenerative disorder. While further assessment of the data is currently underway, according to Huhn, “We are encouraged by the emerging safety profile of the cells and the favorable preliminary efficacy data observed in the measurements of best corrected visual acuity, contrast sensitivity and optical coherence tomography.” Based on the strength of these results, the Company is now enrolling patients for its Phase II proof-of-concept trial in GA-AMD. (Original Source)

Shares of StemCells closed yesterday at $0.51, down $0.002 or 0.39%. STEM has a 1-year high of $2.17 and a 1-year low of $0.49. The stock’s 50-day moving average is $0.65 and its 200-day moving average is $0.89.

On the ratings front, StemCells has been the subject of a number of recent research reports. In a report issued on June 30, Maxim Group analyst Jason Kolbert reiterated a Buy rating on STEM, with a price target of $5, which implies an upside of 880.4% from current levels. Separately, on June 22, Cantor Fitzgerald’s Caroline Corner reiterated a Buy rating on the stock and has a price target of $2.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Kolbert and Caroline Corner have a total average return of -3.4% and -16.7% respectively. Kolbert has a success rate of 34.1% and is ranked #3563 out of 3694 analysts, while Corner has a success rate of 30.0% and is ranked #3591.

StemCells Inc is engaged in the research, development, and commercialization of cell-based stem cell therapeutics and related enabling technologies.